Startup profile for Mirendil: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Mirendil funding, valuation and investors

AI-for-science platform training models expert at AI R&D for autonomous experiments.

Keep track of Mirendil

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Seed

Amount not disclosed · June 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

seed

Investors in latest funding

Lead: Andreessen Horowitz

Sources: latest funding Last verified: 2026-07-25

Overview

Mirendil builds AI systems specialized in AI research and development — enabling scientists to run autonomous experiments and compress discovery cycles. Andreessen Horowitz led the seed round. Team includes alumni from Anthropic, Google, and xAI.

Why Mirendil is interesting

a16z led seed for 'AI that does AI research' — team from Anthropic, Google, and xAI signals VCs treating autonomous science as infrastructure, not novelty.

Product & use cases

Mirendil trains models that are expert at AI R&D workflows — experiment design, hypothesis testing, and iterative research — so domain scientists can delegate technical AI research loops to autonomous systems.

  • Autonomous AI research experiment loops
  • Accelerating scientific discovery with AI agents
  • AI R&D automation for biotech and deep-tech labs

Key facts

  • Seed (Jun 2026): a16z led — a16z announcement
  • Team from Anthropic, Google, xAI

Funding history (newest first)

Investors in our directory

Funds linked from Mirendil's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Team DNA from frontier AI labs (Anthropic, xAI) applied to science automation — not generic LLM wrappers.

AI-for-science is crowded with hype but few deployed systems. Mirendil's wedge is meta — AI that improves AI research itself. Different from drug-discovery plays (Isomorphic) or coding agents (Devin). Execution risk is high; a16z seed validates thesis interest.

  • FutureHouse direct

    AI agents for scientific discovery.

  • Cognition (Devin) adjacent

    AI software engineering agents.

  • Google DeepMind incumbent

    Research lab with science AI programs.

  • Isomorphic Labs adjacent

    AI drug discovery from DeepMind spin-out.

Notable stories

  • a16z led Mirendil's seed arguing autonomous AI research systems could compress scientific discovery cycles — per a16z announcement June 2026.

Industries

AI & Machine Learning Deep Tech Biotech & Life Sciences

Related funding articles

Venture Capital Tracker pieces that cover Mirendil's financing or category context.

FAQs about Mirendil

Practical answers founders, operators, and investors typically search for.

AI platform training models expert at AI R&D for autonomous scientific experiments.
a16z (/fund/andreessen-horowitz) led the seed.
Alumni from Anthropic, Google, and xAI per a16z announcement.
Both target AI-for-science; Mirendil focuses on AI R&D automation specifically.
Systems that run iterative research loops autonomously rather than assisting human researchers.
Not publicly disclosed; seed-stage.
June 2026 seed led by a16z.
Devin targets software engineering. Mirendil targets AI research and scientific R&D.
Thesis that autonomous AI research compresses discovery cycles.
a16z-backed deep-tech AI company.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.